FDA Weighs Peptide Compounding Rules | Fargo News

The FDA is convening a high-stakes two-day meeting to decide whether compounding pharmacies should be allowed to manufacture seven popular injectable peptides—including TB-500 and BPC-157—despite lacking rigorous clinical trials. These substances, touted for everything from injury recovery to anti-aging, are booming in the wellness world, with telehealth and spas aggressively marketing them. While proponents argue current bans drive demand into unsafe overseas markets, critics warn of unproven risks like cancer promotion or immune reactions. Health Secretary Robert F. Kennedy Jr. backs loosening restrictions, and the FDA’s advisory panel now includes industry-linked members—though its own scientists urge caution. Even if the FDA declines to reclassify these peptides, doctors may still prescribe them off-label. The debate hinges on balancing innovation with safety in a rapidly evolving, unregulated market. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0f7c78adfc5062c2